Aduro Biotech Announces Upcoming Data Presentations at the Society for Immunotherapy of Cancer’s 32nd Annual Meeting
October 09 2017 - 8:00AM
Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical company with
three distinct immunotherapy technologies, today announced data
presentations relating to its technology platforms to be given at
the Society for Immunotherapy of Cancer’s 32nd Annual Meeting
taking place in National Harbor, Maryland, November 8-12, 2017.
Poster
335: |
Characterization of a novel differentiated anti-CTLA-4 antibody
(ADU-1604) in vitro and in vivo |
|
Date/Time: Friday, November 10, 12:30 p.m. to 2:00 p.m.
EST |
|
Poster Hall
Location: Prince George’s Exhibition Hall DE |
|
|
Poster
61: |
Cellular
and genomic disease signature of peripheral blood mononuclear cells
in patients with malignant pleural mesothelioma |
|
Date/Time: Friday, November 10, 12:30 p.m. to 2:00 p.m.
EST |
|
Poster Hall
Location: Prince George’s Exhibition Hall DE |
|
|
Poster
133:
|
A
heterologous prime-boost vaccination strategy combining a Listeria
and DNA-based vaccine encoding prostatic acid phosphatase (PAP)
elicits a strong antigen-specific, anti-tumor response |
|
Date/Time: Friday, November 10, 12:30 p.m. to 2:00 p.m.
EST |
|
Poster Hall
Location: Prince George’s Exhibition Hall DE |
Per SITC guidelines, abstracts are embargoed until 8:00 a.m. EST
on November 7, 2017. To view abstracts, please visit the SITC
website at https://www.sitcancer.org/2017/abstracts/info.
About Aduro Aduro Biotech, Inc. is an
immunotherapy company focused on the discovery, development and
commercialization of therapies that transform the treatment of
challenging diseases. Aduro's technology platforms, which are
designed to harness the body's natural immune system, are being
investigated in cancer indications and have the potential to expand
into autoimmune and infectious diseases. Aduro's LADD technology
platform is based on proprietary attenuated strains of Listeria
that have been engineered to express tumor-associated antigens to
induce specific and targeted immune responses. This platform is
being developed as a treatment for multiple indications, including
mesothelioma, gastric, ovarian, lung and prostate cancers.
Additionally, a personalized form of LADD, or pLADD, is in Phase 1
development utilizing tumor neoantigens that are specific to an
individual patient’s tumor. Aduro's STING Pathway Activator
platform is designed to activate the STING receptor in immune
cells, resulting in a potent tumor-specific immune response.
ADU-S100 is the first STING Pathway Activator compound to enter the
clinic and is currently being evaluated in both a Phase 1
monotherapy study as well as a Phase 1b combination study with an
anti-PD1 immune checkpoint inhibitor. Aduro’s B-select monoclonal
antibody platform is comprised of a number of immune modulating
assets in research and preclinical development, including
BION-1301, an anti-APRIL antibody. Aduro is collaborating with
leading global pharmaceutical companies to expand its products and
technology platforms. For more information, please visit
www.aduro.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for
purposes of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements include
statements regarding our intentions or current expectations
concerning, among other things, our technology platforms, plans,
and the potential for eventual regulatory approval of our product
candidates. In some cases, you can identify these statements by
forward-looking words such as “may,” “will,” “continue,”
“anticipate,” “intend,” “could,” “project,” “seek”, “expect” or the
negative or plural of these words or similar expressions.
Forward-looking statements are not guarantees of future
performance and are subject to risks and uncertainties that could
cause actual results and events to differ materially from those
anticipated, including, but not limited to, our history of net
operating losses and uncertainty regarding our ability to achieve
profitability, our ability to develop and commercialize our product
candidates, our ability to use and expand our technology platforms
to build a pipeline of product candidates, our ability to obtain
and maintain regulatory approval of our product candidates, our
inability to operate in a competitive industry and compete
successfully against competitors that have greater resources than
we do, our reliance on third parties, and our ability to obtain and
adequately protect intellectual property rights for our product
candidates. We discuss many of these risks in greater detail
under the heading “Risk Factors” contained in our quarterly report
on Form 10-Q for the quarter ended June 30, 2017, which is on file
with the Securities and Exchange Commission. Any forward-looking
statements that we make in this press release speak only as of the
date of this press release. We assume no obligation to update our
forward-looking statements whether as a result of new information,
future events or otherwise, after the date of this press
release.
Contact:Sylvia WheelerSVP, Corporate Affairs510 809 9264
Media Contact:Susan Lehner510 809 2137press@aduro.com
Aduro Biotech (NASDAQ:ADRO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aduro Biotech (NASDAQ:ADRO)
Historical Stock Chart
From Apr 2023 to Apr 2024